If a deal goes down, my opinion, it needs to be at $10+ per share

???????  Stock is at 13¢, repeated study primary end point failures (4 by my count), in debt, COVID study aborted, no clear path forward.

As per this article, the biggest premium paid for a biotech since 2015 is 282% of the share price, and that's in a perfect storm.  That would be 37¢ a share for RVX.

If the company was sold, I'd be gobsmacked if it was for more than 20¢ CAD a share.